Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.035
+0.035 (3.50%)
At close: Dec 5, 2025, 4:00 PM EST
1.080
+0.045 (4.39%)
After-hours: Dec 5, 2025, 7:47 PM EST
Company Description
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics.
It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022.
Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Revelation Biosciences, Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | James Rolke |
Contact Details
Address: 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 United States | |
| Phone | 650 800 3717 |
| Website | revbiosciences.com |
Stock Details
| Ticker Symbol | REVB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001810560 |
| CUSIP Number | 76135L705 |
| ISIN Number | US76135L7055 |
| Employer ID | 84-3898466 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James M. Rolke | Chairman and Chief Executive Officer |
| Chester Stanley Zygmont III | Chief Financial Officer and Corporate Secretary |
| Sandra Vedrick | Vice President of Human Resources and Investor Relations |
| Carol Odle | Senior Director of Clinical Projects |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 3, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G | Filing |
| Nov 12, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 10, 2025 | DEF 14A | Other definitive proxy statements |
| Nov 6, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Oct 30, 2025 | PRE 14A | Other preliminary proxy statements |
| Oct 29, 2025 | 8-K | Current Report |
| Oct 15, 2025 | 8-K | Current Report |
| Sep 30, 2025 | EFFECT | Notice of Effectiveness |